These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says
Investors are underappreciating the impact generative artificial intelligence will have on biotech stocks, according to Jefferies. Biotech stocks have had a challenging couple of years, falling into a correction after an initial surge at the onset of the coronavirus pandemic, as they navigated a higher interest rate environment. More recently, tariffs and staffing reductions at the U.S. Department of Health and Human Services have also hit the sector. The SPDR S & P Biotech ETF (XBI) is down more than 11% in 2025, while the S & P 500 has eked out a slight gain. XBI YTD mountain XBI Nevertheless, the sector is set to get a boost from the adoption of generative AI in drug discovery, which Michael Yee, senior biotech analyst at Jefferies, said will save companies years and billions of dollars in getting new drugs to market. "We know that biotech is a billion dollars to find a drug, up to 10 years to get a drug to market, and 90% of drugs fail," Yee told CNBC's David Faber on "Squawk on the Street" on Wednesday. "So, we think that based on analysis and some of the technologies these companies are doing, you can cut the drug time by years, and cut the probabilities significantly in half to get drugs to market, and that can save billions of dollars and increase the odds of success and return on investment for companies and investors." "It is very early stage, and we're out there saying, five years from now, we think we'll see tremendous progress in drugs that are in the clinic from test tubes today that were basically done using generative AI," Yee continued. "We can cut a 10 year process, we'd be down to seven of eight years." To be sure, there are some near-term regulatory challenges the sector is facing, but Yee said he expects that any downside from negative headlines is already priced into the stocks. "We're actually optimistic for the rest of the year," he said. Here are some stocks poised to benefit: Amgen , one of the world's largest biotech companies, is one firm integrating generative AI to analyze human datasets for its research. The buy-rated stock is up 7% this year, according to the CNBC analyst consensus tool. Software company Schrodinger is set to benefit from increased research and development spending, using machine learning in drug discovery programs. The stock is up 11% this year. Illumina , which develops systems for genetic variation analysis, and Danaher, a life sciences and diagnostics company, are two other companies to benefit. The stocks are down 38% and 17% this year, respectively.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
22 minutes ago
- CNBC
Chicago PMI surprises to downside
CNBC's Rick Santelli joins 'Squawk on the Street' to discuss the latest economic data to cross the tape.
CNBC
an hour ago
- CNBC
Jim Cramer says his second-half playbook for investors is quite simple
Jim Cramer's second-half playbook for investors is all about getting back to the basics. On CNBC's "Squawk on the Street," Cramer had a straightforward response when asked where investors should put their focus in the coming months. Choose stocks in companies that are "doing well," he said Monday, shortly before the opening bell, as the S & P 500 looked to build off Friday's first record close since February. His comments came in the waning hours of a wild first half of 2025 — driven by on-and-off-again tariffs and, more recently, concerns about a broader regional conflict in the Middle East. Monday is the last trading day of a strong June and a strong second quarter. Cramer acknowledged that his advice might seem almost too simple — but he said he is trying to cut through the noise that might distract everyday investors. In particular, he took issue with the near-constant debate about the Federal Reserve's next move on interest rates. His remarks echo what he wrote in his weekly Sunday column for CNBC Investing Club members. Cramer said Monday he is trying to push back on "the idea that we're supposed to think about getting out of stocks, the Fed is not going to ease enough — instead of looking at companies that are doing well and buying them." Oracle is a prime example of this, according to Cramer. Shares of the technology giant with a booming cloud-computing business surged in response to earnings earlier this month. On Monday, the stock jumped another 5% after Oracle disclosed in a regulatory filing that it signed "multiple large cloud services agreements, including one that is expected to contribute more than $30 billion in annual revenue" starting in fiscal 2028. "That's not Oracle trading with the Fed," Cramer said, referring to Monday's stock gains. "That's trading with Oracle having a new business model that took it from $110 [a share] to $223. That's of great interest to many of our viewers because they made a lot of money."
Business Insider
an hour ago
- Business Insider
Stocks are back in 'meltup' mode after a wild first half — and the S&P 500 could soar 60% by 2030, market vet says
Chaos in markets sparked a lot of bearish prognostications in the first half, but investors have pushed through, and stocks look like they're back in "meltup mode." That's the view of Ed Yardeni, a longtime forecaster and the president of Yardeni Research. His "melt-up" thesis says the stock market embarked on a 1990s-style bull run starting in 2024, a stellar but ultimately unsustainable stock rally similar to what markets saw at the height of the dot-com bubble. To Yardeni, the S&P 500 reaching a new record last week confirms that the formation of a speculative bubble is one of the biggest risks to investors at the moment. Yardeni says he anticipates the S&P 500 reaching 6,500 by the end of the year, a gain of about 5% from levels on Monday. However, by the end of the decade, Yardeni's meltup thesis sees the benchmark index rising to 10,000, representing a 60% gain. "So far, the current bull market looks like a normal one, with the potential to match the returns of some of the best bull markets since the mid-1960s," Yardeni said. The upward climb in stocks is partly due to the continued strength of the US economy, the market vet told CNBC on Friday. While some economic data—like retail sales—has come in weaker-than-expected in recent months, that has largely reflected temporary uncertainties like tariffs. Stocks rallied to records last week on a handful of catalysts. Investors cheered Trump's announcement that the US and China had agreed to a framework trade agreement, and the market continued to rise to fresh records on Monday as investors digested further progress. Canada on Monday said it would cancel a digital services tax that had caused Trump to threaten to end trade talks. "Clearly, trade isn't a done issue yet, but I think will be by the end of the summer," Yardeni said. "You put it all together and I think it's a pretty solid economy, pretty solid stock market," he later added.
